Compare REFR & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | REFR | MDXH |
|---|---|---|
| Founded | 1965 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | |
| Sector | Miscellaneous | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6M | 21.1M |
| IPO Year | 1995 | 2021 |
| Metric | REFR | MDXH |
|---|---|---|
| Price | $0.55 | $0.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 54.3K | ★ 772.9K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,488,642.00 | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | N/A | $18.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.48 | $0.40 |
| 52 Week High | $2.70 | $5.33 |
| Indicator | REFR | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 37.03 | 33.26 |
| Support Level | $0.48 | N/A |
| Resistance Level | $0.83 | $3.79 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 41.35 | 47.66 |
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. The company's revenue source comes from the licensing of technology.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.